CClinicalTrials.gg
CompletedNCT04604808QoL-hPTPUpdated Dec 17, 2021

Study on the Effects of Hypoparathyroidism on Post-thyroidectomy Health-related Quality of Life (QoL-hPTP)

An observational study in Hypoparathyroidism Postprocedural, sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-17.

Sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

Our study will evaluate the health related quality of life (HRQoL) after a thyroidectomy and the relevance of postoperative hypoparathyroidism. The patients submitted to a total thyroidectomy will be evaluated with three questionaries (SF-36, Hospital HADS and a specifically designed Likert-type questionary about the intensity of hypoparathyroidism symptoms). The first evaluation will be before the surgery, and the other two will be completed a week and a month after the procedure.

Read the detailed description

Patients submitted to total thyroidectomy according to clinical practice will be invited to participate in this study. If they accept, they will have to complete three questionaries to evaluate their HRQoL: SF-36, Hospital Anxiety and Depression Scale (HADS) and a specifically designed Likert-type questionary about the intensity of hypoparathyroidism symptoms; the day before the surgery and one week and one month after it. In those cases that develop permanent hypoparathyroidism, an additional evaluation will be done 3, 6, 9 and 12 months after surgery.

Variables:

  • Demographic variables: sex, age, BMI, personal background, previous treatment.
  • Diagnosis variables: diagnosis, cytology (Bethesda System), preoperative laboratory values serum (albumin, glomerular filtrate rate, total and ionic calcium, phosphate, magnesium, parathormone (PTH), 25-hydroxide (OH) vitamin D, thyroid-stimulating hormone (TSH), T4, thyroid antibodies).
  • Procedure variables: central compartment dissection, accidental parathyroidectomy, parathyroid autotransplant, surgery length, intraoperative complications.
  • Post-operative variables:
  • Laboratory test 24h after surgery: albumin, glomerular filtrate rate, total and ionic calcium, phosphate, magnesium, PTH, 25-OH vitamin D.
  • Symptoms of Hypocalcemia: presence of spontaneous symptoms of hypocalcemia, such as paresthesias, and time from the surgery (measured in hours).
  • Postoperative hypocalcemia: defined by a serum albumin-corrected calcium level below 8 mg/dL or by the presence of hypocalcemic symptoms that require calcium or vitamin D supplementation.
  • Follow-up variables: all the patients will be evaluated one week and one month after surgery. When they develop a hypocalcemia, laboratory test will be repeated according to clinical practice. In all cases, this test will be repeated one month after surgery, together with thyroid function test. The need for oral supplementation of calcium and/or vitamin D analogs or even magnesium will be collected (doses and time needed). The definitive histological diagnosis and the number of additional parathyroid glands identified in the surgical specimen will be also collected. In cases that developed postoperative hypocalcemia, the investigators will record the time to resolution, defined as the absence of calcium or vitamin D supplementation and a PTH level above 13 pg/mL.

Statistical Analysis:

The patients will be divided into two group depending on the development of post-thyroidectomy hypoparathyroidism. The results of their HRQoL questionaries will be compared within both groups. The investigators will evaluate the influence of clinical variables on these results.

The quantitative variables that follow a normal distribution will be described by the mean and the standard deviation; and those who do not follow the normal distribution will be described by median and interquartile range. The qualitative variables will be defined by the number of events and the percentage. To know if the variable follow or not the normality the investigators will use de Kolmogorov-Smirnov test.

The quantitative variables with a normal distribution will be compared with Student t-test (if there are two means) or with ANOVA (for more than two means). To compare quantitative variables with a different distribution, the Mann-Whitney U test (2 means) or Kruskal-Wallis test (more than 2) will be use.

The association between quantitative variable with a normal distribution will be stablished by the Pearson correlation ratio; and for those who do not follow the normal distribution, with Spearman test.

χ2 test will be used to compare qualitative variables. If an absolute frequency less or equal to 5 is found in any of the contingency table cells, the Fisher's exact test will be used.

Every test will be considered if there is a minimum signification level of p\<0,05.

Sample size calculation:

There is not enough published data in order to help us calculate a proper sample size. the investigators will conduce the first 40 patients as a pilot study, based on which it will estimate a definitive sample size. The investigators will take as reference the results of the SF-36 survey of the week after the surgery and a minimum difference to detect of the 10% of the punctuation.

02

Conditions studied

  • Hypoparathyroidism Postprocedural

Browse trials for

Keywords

  • Health-related Quality of Life
  • Thyroidectomy
  • Postoperative hypoparathyroidism
03

In context

Hypoparathyroidism

120 studies on the registry are indexed under Hypoparathyroidism; 29 are open to participants now.

This study's enrollment of 40 is below the median of 127 across 46 observational studies indexed under Hypoparathyroidism.

Browse Hypoparathyroidism studies →

Lead sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa is the lead sponsor of 34 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients submitted to total thyroidectomy according to clinical practice.

Inclusion criteria

  • Patients submitted to total thyroidectomy
  • Patients older than 18 yo
  • Patients who accept participating in the study.
  • Patients who, before the surgery, have done a complete laboratory test.
  • Patients followed for at least one month after surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients submitted to a subtotal or completion thyroidectomy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No

Groups and cohorts

  • Non hypocalcemic group

    Patients that don't develop post-thyroidectomy hypocalcemia

  • Hypocalcemic group

    Patients that develop post-thyroidectomy hypocalcemia

06

What researchers measure

Primary outcomes

  1. Change in SF-36 score

    36-Item Short Form Health Survey questionnaire: 0 to 100 points, been a lower score a worse outcome

    Time frame: Preoperative, one week and one month after surgery

  2. Change in HADS score

    Hospital Anxiety and Depression Scale: 0 to 42 points, been a higher score a worse outcome

    Time frame: Preoperative, one week and one month after surgery

  3. Changes Questionary of hypocalcemia symptoms

    Specifical designed Liker-type questionary: Likert scale based score, from 1 to 10 points, been a higher score a worse outcome

    Time frame: Preoperative, one week and one month after surgery

07

Study locations

1 site
  • Hospital Universitario de La princesa
    Madrid, 28006, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04604808
Lead sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Responsible party
Jose Luis Muñoz de Nova (Endocrine Surgeon Consultant, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa) — Principal investigator
First posted
Oct 27, 2020
Start date
Oct 1, 2020
Primary completion
Mar 31, 2021
Completion
Nov 30, 2021
Last update
Dec 17, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion